Offerings include target identification, target validation, biomarker discovery, and RNAi therapeutic technology development.
Thermo Fisher Scientific opened an RNAi Discovery and Therapeutic Services laboratory. The facility offers advanced RNAi screening and analysis services as well as development of new therapeutic technologies involving RNAi. The lab is based at its RNAi research and production center in Lafayette, CO.
“Our core expertise in RNAi biology and therapeutic technology development, high-throughput screening, RNA chemistry, and drug discovery research combined with our unique portfolio of bioreagents, instrument systems, and robotics, enables us to perform highly advanced contract services in-house,” according to Marc N. Casper, executive vp of Thermo Fisher Scientific.
The RNAi contract services provides critical drug discovery activities and supplemental resources and expertise for overburdened labs already using RNAi technology. Services range from a single screen to multicomponent projects and include RNAi-based high-throughput screening and hit validation, high-content screening, miRNA expression profiling and analysis, as well as lab automation and integration. Therapeutic discovery and technology development is also available for clients pursuing RNAi-based therapeutics.
